Abe Bassan

Abe Bassan is a Principal at Samsara BioCapital, a life science investment firm dedicated to building companies that advance innovative medicines. Prior to joining Samsara, he held operation roles at Revolution Medicines and Bluebird Bio, and before that was an Associate at Third Rock Ventures. Abe received an A.B. in Molecular Biology from Princeton University, and an M.S. in Developmental Biology from Stanford University. Abe serves as a director on the boards of Graphite Bio, Septerna, CARGO Therapeutics, and Vedere Bio II.